RBC Capital raised the firm’s price target on Bio-Rad (BIO) to $469 from $446 and keeps an Outperform rating on the shares. The company beat EBITDA estimates by over $30M with $4M-$5M coming from higher royalties and the rest of the beat broad based from mix, efficiencies, spending control, and better than expected revenue growth in both segments, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIO:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue